Literature DB >> 34021129

UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer.

Congcong Zhu1,2, Long Zhang1,2, Senlin Zhao1,2, Weixing Dai1,2, Yun Xu1,2, Yuqin Zhang1,2, Hongtu Zheng1,2, Weiqi Sheng3,4, Ye Xu5,6.   

Abstract

UPF1 is proved to dysregulate in multiple tumors and influence carcinogenesis. However, the role of UPF1 in oxaliplatin resistance in colorectal cancer (CRC) remains unknown. In our study, UPF1 is upregulated in CRC in mRNA and protein levels and overexpression of UPF1 predicts a poor overall survival (OS) and recurrence-free survival (RFS) in CRC patients and is an independent risk factor for recurrence. UPF1 promotes chemoresistance to oxaliplatin in vitro and in vivo. UPF1-induced oxaliplatin resistance can be associated with interaction between zinc finger of UPF1 and Toprim of TOP2A and increasing phosphorylated TOP2A in a SMG1-dependent manner. Moreover, UPF1 maintains stemness in a TOP2A-dependent manner in CRC. Taken together, UPF1 was overexpressed and predicted a poor prognosis in CRC. UPF1 enhanced chemoresistance to oxaliplatin in CRC, which may result from regulation of TOP2A activity and maintenance of stemness. Our findings could provide a new therapy strategy for chemoresistance to oxaliplatin in CRC patients.

Entities:  

Year:  2021        PMID: 34021129     DOI: 10.1038/s41419-021-03798-2

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  51 in total

Review 1.  The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision.

Authors:  Susana Roselló; Federica Papaccio; Desamparados Roda; Noelia Tarazona; Andrés Cervantes
Journal:  Cancer Treat Rev       Date:  2018-01-11       Impact factor: 12.111

Review 2.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Authors:  Mustafa Suker; Berend R Beumer; Eran Sadot; Lysiane Marthey; Jason E Faris; Eric A Mellon; Bassel F El-Rayes; Andrea Wang-Gillam; Jill Lacy; Peter J Hosein; Sing Yu Moorcraft; Thierry Conroy; Florian Hohla; Peter Allen; Julien Taieb; Theodore S Hong; Ravi Shridhar; Ian Chau; Casper H van Eijck; Bas Groot Koerkamp
Journal:  Lancet Oncol       Date:  2016-05-06       Impact factor: 41.316

Review 3.  Immunotherapy in colorectal cancer: rationale, challenges and potential.

Authors:  Karuna Ganesh; Zsofia K Stadler; Andrea Cercek; Robin B Mendelsohn; Jinru Shia; Neil H Segal; Luis A Diaz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06       Impact factor: 46.802

Review 4.  Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.

Authors:  Eva Martinez-Balibrea; Anna Martínez-Cardús; Alba Ginés; Vicenç Ruiz de Porras; Catia Moutinho; Laura Layos; José Luis Manzano; Cristina Bugés; Sara Bystrup; Manel Esteller; Albert Abad
Journal:  Mol Cancer Ther       Date:  2015-07-16       Impact factor: 6.261

Review 5.  Pharmacologic resistance in colorectal cancer: a review.

Authors:  William A Hammond; Abhisek Swaika; Kabir Mody
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

Review 6.  Oxaliplatin in ovarian cancer.

Authors:  C Sessa; W W ten Bokkel Huinink; A du Bois
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

Review 7.  Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.

Authors:  Zhenhua Zhai; Xiaohui Yu; Bin Yang; Yunjing Zhang; Long Zhang; Xiaoli Li; Hongzhi Sun
Journal:  Semin Cell Dev Biol       Date:  2016-08-27       Impact factor: 7.727

8.  Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Authors:  Julien Edeline; Meher Benabdelghani; Aurélie Bertaut; Jérôme Watelet; Pascal Hammel; Jean-Paul Joly; Karim Boudjema; Laetitia Fartoux; Karine Bouhier-Leporrier; Jean-Louis Jouve; Roger Faroux; Véronique Guerin-Meyer; Jean-Emmanuel Kurtz; Eric Assénat; Jean-François Seitz; Isabelle Baumgaertner; David Tougeron; Christelle de la Fouchardière; Catherine Lombard-Bohas; Eveline Boucher; Trevor Stanbury; Christophe Louvet; David Malka; Jean-Marc Phelip
Journal:  J Clin Oncol       Date:  2019-02-01       Impact factor: 44.544

Review 9.  The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Authors:  D Hind; P Tappenden; I Tumur; S Eggington; P Sutcliffe; A Ryan
Journal:  Health Technol Assess       Date:  2008-05       Impact factor: 4.014

10.  Cancer incidence and mortality in China, 2014.

Authors:  Wanqing Chen; Kexin Sun; Rongshou Zheng; Hongmei Zeng; Siwei Zhang; Changfa Xia; Zhixun Yang; He Li; Xiaonong Zou; Jie He
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

View more
  2 in total

Review 1.  Nonsense-mediated RNA decay: an emerging modulator of malignancy.

Authors:  Kun Tan; Dwayne G Stupack; Miles F Wilkinson
Journal:  Nat Rev Cancer       Date:  2022-05-27       Impact factor: 69.800

2.  UPF1 contributes to the maintenance of endometrial cancer stem cell phenotype by stabilizing LINC00963.

Authors:  Hao Chen; Jian Ma; Fanfei Kong; Ning Song; Cuicui Wang; Xiaoxin Ma
Journal:  Cell Death Dis       Date:  2022-03-22       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.